title: Exploring cell apoptosis and senescence to understand and treat cancer: an interview with Scott Lowe.
abstract: Scott W. Lowe is currently principal investigator at the Memorial Sloan-Kettering Cancer Center. After beginning his studies in chemical engineering, he decided to take another path and became fascinated by biochemistry, genetics and molecular biology, which ultimately led to an interest in human disease, particularly cancer. During his PhD at the Massachusetts Institute of Technology (MIT), Scott had the opportunity to benefit from the exceptional mentorship of Earl Ruley, David Housman and Tyler Jacks, and contributed to elucidating how the p53 (TP53) tumor suppressor gene limits oncogenic transformation and modulates the cytotoxic response to conventional chemotherapy. This important work earned him a fellowship from the Cold Spring Harbor Laboratory, which helped to launch his independent career. Scott is now a leading scientist in the cancer field and his work has helped to shed light on mechanisms of cell apoptosis and senescence to better understand and treat cancer. In this interview, he talks about this incredible scientific journey.
authors.forename: Scott
authors.initials: S
authors.lastname: Lowe
authors.forename: Alessandra
authors.initials: A
authors.lastname: Cifra
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000266:history / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D035843:Biomedical Research / Q000266:history*; D002321:Career Choice; D002322:Career Mobility; D016922:Cellular Senescence / Q000187:drug effects; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007587:Job Description; D007857:Leadership; D058990:Molecular Targeted Therapy / Q000266:history; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000266:history* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents